-
10 Years of Successful Partnership between EvidentIQ Germany and Cardialysis in the Field of Clinical Studies
EvidentIQ Germany, formerly known as XClinical, a top provider of EDC software, is proud to mark a decade of fruitful collaboration with Cardialysis, a renowned CRO & Core Laboratory based in the Netherlands. For the past ten years, EvidentIQ Germany and Cardialysis have joined forces to achieve impressive accomplishments in clinical research. Together, they have enrolled over 46,000 participants in 56 studies spanning various therapeutic areas and study phases, with a primary focus on cardiology. This decade has seen significant milestones. EvidentIQ introduced Marvin 3.0, featuring a cutting-edge user interface that enhances the efficiency of data capture and management. Additionally, a noteworthy development for Cardialysis was EvidentIQ’s expansion through the…
-
EvidentIQ is pleased to announce the addition of Asthenis GmbH to their comprehensive eClinical solutions group.
Today, EvidentIQ, a leading provider of end-to-end eClinical and Patient Insights solutions, announced the acquisition of Asthenis GmbH, the market leader in cancer documentation software in the DACH region (Germany, Austria and Switzerland). EvidentIQ, based in Hamburg, is a leading clinical data science group, offering an end-to-end platform of state-of-the art eClinical solutions (eConsent, EDC, CTMS, eCOA,) that helps its customers with the planning and execution of both hybrid/decentralized and traditional clinical trials. Thanks to its global patient platform Carenity, the group combines their technology with a direct access to real-world patient insights, enabling them to support sponsors and CROs with innovative offerings such as eFeasibility, eRecruitment and Real-World Evidence…
-
EvidentIQ Announces Change of Leadership
Today, EvidentIQ, a leading provider of end-to-end eClinical and Patient Insights solutions, proudly announces a strategic leadership restructuring, setting the stage for the company’s continued growth and commitment to delivering unparalleled results for its clients. After three highly successful years of guiding EvidentIQ’s evolution and establishing it as a formidable player in the healthcare industry, Andreas Weber will step down from his role as CEO to focus on leading the Sales efforts. With his wealth of experience in the market, Andreas will be instrumental in driving the Sales team to new heights and achieving even greater success. Dr. Dominique Manu, a seasoned professional with over 15 years of leadership experience…
-
Quinta Analytica Partners with EvidentIQ to Enhance Efficiency of Phase 1 Studies
EvidentIQ, the innovative provider of advanced clinical trial management solutions has joined forces with Quinta Analytica, a renowned GCP/GLP/GMP-certified European CRO and part of the Conscio Group. This collaboration aims to enhance the efficiency and effectiveness of data collection processes for Phase 1 studies, utilizing EvidentIQ’s Clindex eClinical system. According to Dr. Renata Vyhnálková, Quality Assurance Auditor of Quinta, "Collecting data for phase 1 studies requires unique requirements. After evaluating many software solutions, we are thrilled to have finally found a solution that will meet our needs. The EvidentIQ team has worked diligently to help implement Clindex and responded quickly to additional functionality needed during the process.“ Phase 1 clinical…
-
Carenity, part of the EvidentIQ Group, announces change in leadership
Michael Chekroun, founder of Carenity and outgoing President, will be stepping down from his role as of today. Lise Radoszycki, former COO, will be taking the helm as the new President, bringing extensive experience and expertise that will propel the company into its next phase of expansion and development. Michael Chekroun has played for the past 12 years a central role in building and shaping the company, leading it through successful initiatives, strategic partnerships, and most of all creating a sustainable and innovative model that allows patients to share their experiences while making medical knowledge advance. Michael has chosen to step down, two years after selling his company to EvidentIQ,…
-
Managed Service Model for OpenStudyBuilder
EvidentIQ launches a new Managed Service Model that not only supports the use of the open-source solution OpenStudyBuilder, but also helps clients customizing it to their specific requirements. Last year EvidentIQ released alongside Novo Nordisk, Neo4j, and Microsoft, a new solution for managing clinical data standards and study design specifications, the OpenStudyBuilder. In the world of pharmaceuticals, metadata management is crucial for the success of clinical trials. Managing metadata can be a complex task, with several challenges involved, such as data inconsistencies, bottlenecks between systems and processes, and manual work. To simplify this process, EvidentIQ offers a Manage Service Model for OpenStudyBuilder users to support them with their specific requirements.…
-
E2B Mailer: Safety Notifications Made Easy
EvidentIQ launches a new tool designed specifically to bridge the gap between a simple reporting and a PV system. EvidentIQ aspired to create a tool that could solve the problem of having a reliable safety notification tool to monitor adverse drug reactions (ADRs) outside of the scope of a full PV system in a trial or non-interventional study. After much research and engineering time they came up with the E2B Mailer. The E2B Mailer is a new safety notification solution that provides an auto forward functionality of (Serious) Adverse Events in E2B and archivable format. It has the great advantage of being EDC agnostic, so it can adapt to any…
-
EvidentIQ and Keyrus Life Science are building a strategic partnership
Today, EvidentIQ, a leading clinical data science group and Keyrus Life Science, the Connected Contract Research Organization (C²RO), announced the signing of their partnership. The synergy between both companies will improve automation, efficiency and agility in clinical research by leveraging new eClinical capabilities. EvidentIQ, based in Hamburg, is a leading clinical data science group, offering state-of-the art eClinical solutions (eConsent, EDC, CTMS, eCOA, RWE). Keyrus Life Science, operating across Europe and North America, connects CRO expertise, life data science and digital enablement to fully leverage both clinical research ecosystems and real-world evidence to help organizations shape better their clinical research trial strategies. “I’m very proud to be able to announce…
-
EvidentIQ welcomes DACIMA Software into their end-to-end eClinical solutions group.
Today, EvidentIQ, a leading provider of end-to-end eClinical and Patient Insights solutions, announced the acquisition of DACIMA Software, a Canadian clinical software company founded in 2006. EvidentIQ, based in Hamburg, is a leading clinical data science group, offering an end-to-end platform of state-of-the art eClinical solutions (eConsent, EDC, CTMS, eCOA,) that helps its customers with the planning and execution of both hybrid/decentralized and traditional clinical trials. Thanks to its global patient platform Carenity, the group combines their technology with a direct access to real-world patient insights, enabling them to support sponsors and CROs with innovative offerings such as eFeasibility, eRecruitment and Real-World Evidence data collection and analysis Dacima, based in…
